EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of a new triphasic oral contraceptive in private practice






Contraception 34(5): 435-442

Evaluation of a new triphasic oral contraceptive in private practice

We evaluated the clinical and metabolic effects of a new triphasic regimen developed in the continuing attempt to reduce the dose of estrogen and progesteron in oral contraceptives. A combination of ethinyl estradiol (EE) and levonorgestrel (LNg) was used (six tablets with 30 .mu.g EE + 50 .mu.g LNg, five tablets with 40 .mu.g EE + 75 .mu.g LNg, and 10 tablets with 30 .mu.g EE + 125 .mu.g LNg), also known as Triphasil (Wyeth). In a private practice, 409 subjects participated in 7,286 treatment cycles. Three pregnancies occurred, all due to subject failure. Menstrual regulation was excellent and the incidence of side effects extremely low. Withdrawals from the study for possibly drug-related medical reasons totaled 9.0% through 56 cycles of treatment. Metabolic changes also were evaluated in 14 of these women over a 6-month period. The only statistically significant increased in carbohydrate values occurred at 6 months. The mean glucose level at 30 minutes of the oral glucose tolerance test was above the baseline mean value, but serum insulin levels showed no statistically significant deviation. Lipid values presented are total lipids, total cholesterol, triglycerides, .alpha.-, .beta.-, and pre-.beta.-lipoproteins, and high density and low density lipoprotein cholesterol. There was no statistically significant difference between the mean values at the baseline and those during treatment for any lipid variable. These results indicate that this triphasic oral contraceptives has a high degree of efficacy, a low incidence of side effects, excellent cycle control, and high subject compliance, and would seem to indicate a minimal influence on the metabolism of lipids and carbohydrates in the small number of subjects studied.

Accession: 005395451

PMID: 3102161

DOI: 10.1016/0010-7824(86)90053-3

Download PDF Full Text: Evaluation of a new triphasic oral contraceptive in private practice



Related references

Clinical evaluation of a new triphasic oral contraceptive: Norgestimate and ethynylestradiol. Acta Obstetricia et Gynecologica Scandinavica 71(156 SUPPL.): 27-32, 1992

Evaluation and therapy of breakthrough bleeding in women using a triphasic oral contraceptive. Fertility and Sterility 55(2): 292-296, 1991

Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstetricia et Gynecologica Scandinavica. Supplement 156: 9-14, 1992

Contraceptive compliance with a levonorgestrel triphasic and a norethindrone monophasic oral contraceptive in adolescent patients. American Journal of Obstetrics & Gynecology 166(3): 901-907, 1992

Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile. Journal of Clinical Pharmacology 44(6): 646-654, 2004

A quantitative biometrological assessment of acne and hormonal evaluation in young women using a triphasic low-dose oral contraceptive containing gestodene. European Journal of Contraception & Reproductive Health Care 5(4): 275-286, 2001

Norethindrone And Mestranol. Experience In Private Practice With A New Low-Dosage Oral Contraceptive. Ohio State Medical Journal 60: 548-550, 1964

A low-dose triphasic oral contraceptive. Fertility and Sterility 47(3): 425-430, 1987

Rationale for a triphasic oral contraceptive. Journal of Reproductive Medicine 29(7 Suppl): 560-567, 1984

Triphasil--a new triphasic oral contraceptive. Medical Letter on Drugs and Therapeutics 27(688): 48-48, 1985